Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Veliparib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 20/20 | 1.00 |
| ▸ | PARP2 known ✓ | Q9UGN5 | 6/20 | 1.00 |
| ▸ | PARP3 known ✓ | Q9Y6F1 | 1/20 | 0.98 |
| ▸ | TNKS | O95271 | 1/20 | 0.98 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.98 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.98 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.98 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.98 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Veliparib SCHEMBL2368887 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL2368889 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL2368883 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL30418660 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL422319 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL29354914 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL422318 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL422320 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL5511373 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL29843298 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011881-A1 | MYC-HSF1 DUAL AMPLIFICATION AS A BIOMARKER FOR CANCER TREATMENT | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2025-01-09 | — | — | US | disclosed |
| US-20240309458-A1 | MYC-HSF1 DUAL AMPLIFICATION AS A BIOMARKER FOR CANCER TREATMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-09-19 | — | — | US | disclosed |
| US-11638709-B2 | Rucaparib, Talazoparib, Veliparib, Olaparib and AZD 2461 for treating impaired skin wound healing | AKRIBES BIOMEDICAL GMBH (AT) | 2023-05-02 | — | — | US | disclosed |
| US-20220110882-A1 | SYNTHETICALLY LETHAL NANOPARTICLES FOR TREATMENT OF CANCERS | UNIV IOWA RES FOUND (US) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638709-B2 | Rucaparib, Talazoparib, Veliparib, Olaparib and AZD 2461 for treating impaired skin wound healing | PARP1, PARP11, RAD1 | PARP1 1/4885PARP2 6/4885PARP3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.